Comparative Pharmacology
Head-to-head clinical analysis: SETHOTOPE versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SETHOTOPE versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
SETHOTOPE vs TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Technetium Tc 99m albumin aggregated is a radiopharmaceutical that localizes in the pulmonary capillary bed by capillary blockade, allowing for lung perfusion imaging. The aggregated albumin particles are trapped in the pulmonary capillaries, and the Tc 99m emits gamma radiation detectable by gamma cameras.
1.0 mg IV every 12 hours for 7 days.
1-4 mCi (37-148 MBq) intravenous injection for lung perfusion imaging. Single dose per imaging session.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Physical half-life of Tc-99m is 6.02 hours; biological half-life of aggregated albumin in lungs is 2-4 hours due to enzymatic degradation and clearance.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Renal: 30-40% within 24 hours (free pertechnetate); fecal: <1% (minor); remainder accumulated in reticuloendothelial system with slow release.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical